531 related articles for article (PubMed ID: 27007464)
1. Nodal expression in triple-negative breast cancer: Cellular effects of its inhibition following doxorubicin treatment.
Bodenstine TM; Chandler GS; Reed DW; Margaryan NV; Gilgur A; Atkinson J; Ahmed N; Hyser M; Seftor EA; Strizzi L; Hendrix MJ
Cell Cycle; 2016 May; 15(9):1295-302. PubMed ID: 27007464
[TBL] [Abstract][Full Text] [Related]
2. Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.
Jabbour-Leung NA; Chen X; Bui T; Jiang Y; Yang D; Vijayaraghavan S; McArthur MJ; Hunt KK; Keyomarsi K
Mol Cancer Ther; 2016 Apr; 15(4):593-607. PubMed ID: 26826118
[TBL] [Abstract][Full Text] [Related]
3. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
4. The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer.
Fatima I; El-Ayachi I; Taotao L; Lillo MA; Krutilina RI; Seagroves TN; Radaszkiewicz TW; Hutnan M; Bryja V; Krum SA; Rivas F; Miranda-Carboni GA
PLoS One; 2017; 12(12):e0189864. PubMed ID: 29281678
[TBL] [Abstract][Full Text] [Related]
5. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells.
Bilir B; Kucuk O; Moreno CS
J Transl Med; 2013 Nov; 11():280. PubMed ID: 24188694
[TBL] [Abstract][Full Text] [Related]
6. Diterpenoid natural compound C4 (Crassin) exerts cytostatic effects on triple-negative breast cancer cells via a pathway involving reactive oxygen species.
Richards CE; Vellanki SH; Smith YE; Hopkins AM
Cell Oncol (Dordr); 2018 Feb; 41(1):35-46. PubMed ID: 29134467
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
8. PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis.
Paul A; Gunewardena S; Stecklein SR; Saha B; Parelkar N; Danley M; Rajendran G; Home P; Ray S; Jokar I; Vielhauer GA; Jensen RA; Tawfik O; Paul S
Cell Death Differ; 2014 Sep; 21(9):1469-81. PubMed ID: 24786829
[TBL] [Abstract][Full Text] [Related]
9. Quercetin regulates β-catenin signaling and reduces the migration of triple negative breast cancer.
Srinivasan A; Thangavel C; Liu Y; Shoyele S; Den RB; Selvakumar P; Lakshmikuttyamma A
Mol Carcinog; 2016 May; 55(5):743-56. PubMed ID: 25968914
[TBL] [Abstract][Full Text] [Related]
10. PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim.
Byerly JH; Port ER; Irie HY
Breast Cancer Res; 2020 Jun; 22(1):72. PubMed ID: 32600444
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor-α36 is involved in icaritin induced growth inhibition of triple-negative breast cancer cells.
Wang X; Zheng N; Dong J; Wang X; Liu L; Huang J
J Steroid Biochem Mol Biol; 2017 Jul; 171():318-327. PubMed ID: 28529129
[TBL] [Abstract][Full Text] [Related]
12. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylated STAT3 (Tyr705) as a biomarker of response to pimozide treatment in triple-negative breast cancer.
Dees S; Pontiggia L; Jasmin JF; Mercier I
Cancer Biol Ther; 2020 Jun; 21(6):506-521. PubMed ID: 32164483
[TBL] [Abstract][Full Text] [Related]
14. Piperlongumine Induces Apoptosis and Synergizes with Doxorubicin by Inhibiting the JAK2-STAT3 Pathway in Triple-Negative Breast Cancer.
Chen D; Ma Y; Li P; Liu M; Fang Y; Zhang J; Zhang B; Hui Y; Yin Y
Molecules; 2019 Jun; 24(12):. PubMed ID: 31242627
[TBL] [Abstract][Full Text] [Related]
15. CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers.
Cheriyan VT; Muthu M; Patel K; Sekhar S; Rajeswaran W; Larsen SD; Polin L; Levi E; Singh M; Rishi AK
Oncotarget; 2016 Nov; 7(45):73370-73388. PubMed ID: 27687593
[TBL] [Abstract][Full Text] [Related]
16. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
Salaroglio IC; Gazzano E; Abdullrahman A; Mungo E; Castella B; Abd-Elrahman GEFA; Massaia M; Donadelli M; Rubinstein M; Riganti C; Kopecka J
J Exp Clin Cancer Res; 2018 Nov; 37(1):286. PubMed ID: 30482226
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of aerobic glycolysis enhances the anti-tumor efficacy of Zoptarelin Doxorubicin in triple-negative breast cancer cells.
Gründker C; Wokoun U; Hellriegel M; Emons G
J Obstet Gynaecol Res; 2019 Jul; 45(7):1334-1342. PubMed ID: 31016845
[TBL] [Abstract][Full Text] [Related]
18. Reverse engineering of triple-negative breast cancer cells for targeted treatment.
Bluemel L; von Wahlde MK; Tio J; Kiesel L; Bernemann C
Maturitas; 2018 Feb; 108():24-30. PubMed ID: 29290211
[TBL] [Abstract][Full Text] [Related]
19. Anti-cancer therapeutic benefit of red guava extracts as a potential therapy in combination with doxorubicin or targeted therapy for triple-negative breast cancer cells.
Liu HC; Chiang CC; Lin CH; Chen CS; Wei CW; Lin SY; Yiang GT; Yu YL
Int J Med Sci; 2020; 17(8):1015-1022. PubMed ID: 32410830
[TBL] [Abstract][Full Text] [Related]
20. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
